Literature DB >> 25159455

Disappointing durable remission rates in complex Crohn's disease fistula.

Ilse Molendijk1, Veerle J A A Nuij, Andrea E van der Meulen-de Jong, C Janneke van der Woude.   

Abstract

BACKGROUND: Despite potent drugs and surgical techniques, the treatment of perianal fistulizing Crohn's disease (CD) remains challenging. We assessed treatment strategies for perianal fistulizing CD and their effect on remission, response, and relapse.
METHODS: Patients with perianal fistulizing CD visiting the Erasmus MC between January 1, 1980 and January 1, 2000 were identified. Demographics, fistula characteristics, and received treatments aimed at the outcome of these strategies were noted.
RESULTS: In total, 232 patients were identified (98 male; 42.2%). Median follow-up was 10.0 years (range, 0.5-37.5 yr). Complex fistulas were present in 78.0%. Medical treatment (antibiotics, steroids, immunosuppressants, and anti-tumor necrosis factor) commenced in 79.7% of the patients and in 53.2%, surgery (colectomy, fistulectomy, stoma, and rectum amputation) was performed. Simple fistulas healed more often than complex fistulas (88.2% versus 64.6%; P < 0.001). Rectum involvement was not associated with a lower remission rate, and anti-tumor necrosis factor therapy did not increase complete fistula healing rates in simple and complex fistula. Initially, healed fistulas recurred in 26.7% in case of simple fistulas and in 41.9% in case of complex fistulas (P = 0.051). Only 37.0% of the complex fistulas were in remission at the end of follow-up compared with 66.7% of the simple fistulas (P < 0.001).
CONCLUSIONS: Only the minority of CD complex perianal fistulas were in remission after conventional treatment strategies after a median follow-up of 10 years. Simple fistulas were more likely to heal than complex fistulas, and less of these healed fistulas relapsed. However, more than 3 quarters of the patients had complex perianal fistulas.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25159455     DOI: 10.1097/MIB.0000000000000148

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  31 in total

Review 1.  Recent advances in the management of perianal fistulizing Crohn's disease: lessons for the clinic.

Authors:  Nicole Lopez; Sonia Ramamoorthy; Willam J Sandborn
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2019-04-26       Impact factor: 3.869

Review 2.  Pharmacological Approach to the Management of Crohn's Disease Patients with Perianal Disease.

Authors:  Fernando Bermejo; Iván Guerra; Alicia Algaba; Antonio López-Sanromán
Journal:  Drugs       Date:  2018-01       Impact factor: 9.546

3.  Endorectal Advancement Flaps for Perianal Fistulae in Crohn's Disease: Careful Patient Selection Leads to Optimal Outcomes.

Authors:  Michelle T Roper; Stephen M Trinidad; Sonia L Ramamoorthy; Lisa A Parry; Nicole E Lopez; Sergey Khaitov; Randolph Steinhagen; Samuel G Eisenstein
Journal:  J Gastrointest Surg       Date:  2019-04-12       Impact factor: 3.452

Review 4.  Role of Fecal Diversion in Complex Crohn's Disease.

Authors:  John P Burke
Journal:  Clin Colon Rectal Surg       Date:  2019-07-02

Review 5.  Perianal fistulizing Crohn's disease: pathogenesis, diagnosis and therapy.

Authors:  Julián Panés; Jordi Rimola
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-08-09       Impact factor: 46.802

Review 6.  Stem cell-based therapies in inflammatory bowel disease: promises and pitfalls.

Authors:  Natalie E Duran; Daniel W Hommes
Journal:  Therap Adv Gastroenterol       Date:  2016-04-25       Impact factor: 4.409

Review 7.  Management of complex perianal Crohn's disease.

Authors:  Lara Aguilera-Castro; Carlos Ferre-Aracil; Ana Garcia-Garcia-de-Paredes; Enrique Rodriguez-de-Santiago; Antonio Lopez-Sanroman
Journal:  Ann Gastroenterol       Date:  2016-10-27

8.  Proceedings of the signature series event of the international society for cellular therapy: "Advancements in cellular therapies and regenerative medicine in digestive diseases," London, United Kingdom, May 3, 2017.

Authors:  Rachele Ciccocioppo; Claudia C Dos Santos; Daniel C Baumgart; Giuseppina C Cangemi; Vincenzo Cardinale; Carolina Ciacci; Paolo De Coppi; Debashis Haldar; Catherine Klersy; M Cristina Nostro; Michael Ott; Lorenzo Piemonti; Alice A Tomei; Basak Uygun; Stefania Vetrano; Giuseppe Orlando
Journal:  Cytotherapy       Date:  2018-02-15       Impact factor: 5.414

9.  Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe.

Authors:  Petra Baji; László Gulácsi; Valentin Brodszky; Zsuzsanna Végh; Silvio Danese; Peter M Irving; Laurent Peyrin-Biroulet; Stefan Schreiber; Fanni Rencz; Péter L Lakatos; Márta Péntek
Journal:  United European Gastroenterol J       Date:  2017-05-08       Impact factor: 4.623

10.  How are we managing fistulating perianal Crohn's disease? Results of a national survey of consultant gastroenterologists.

Authors:  Matthew James Lee; Steven R Brown; Nicola S Fearnhead; Ailsa Hart; Alan J Lobo
Journal:  Frontline Gastroenterol       Date:  2017-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.